Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2147836 | 1.00 | KDM1A (0.50) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL29529186 | 1.00 | KDM1A (0.50) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL30316454 | 1.00 | KDM1A (0.50) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL594461 | 1.00 | KDM1A (0.50) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL30664080 | 1.00 | KDM1A (0.50) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL7395445 | 0.98 | KDM1A (0.48) | KDM1AMAOBHDAC9TSHRTDP1 | |
| Acetone SCHEMBL3363093 | 0.91 | KDM1A (0.44) | KDM1AMAOBHDAC9TSHRTDP1 | |
| SCHEMBL6440070 | 0.88 | KDM1A (0.56) | KDM1AMAOBTSHRHTR2AMAPK1 | |
| Trifluoroacetic Acid SCHEMBL4280581 | 0.85 | HDAC9 (0.42) | KDM1AMAOBHDAC9TSHRTDP1 | |
| P-Toluenesulfonamide SCHEMBL5528880 | 0.79 | CA2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560482-B2 | Inhibitors of plasmepsins | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-07-14 | — | — | US | claimed |
| US-20050037953-A1 | Inhibitors of plasmepsins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-17 | — | — | US | claimed |
| CN-1083425-C | Regiospecific process to make cis-1-amino-2-alkanol from epoxide | MERCK & CO INC (US) | 2002-04-24 | — | — | CN | claimed |
| CN-1077881-C | Regiospecific processes to make cis-1-amino-2-alkanol from diol or halohydrin | MERCK & CO INC (US) | 2002-01-16 | — | — | CN | claimed |
| US-6171832-B1 | FERMENTING STARTING MATERIAL IN CULTURE, RECOVERING PRODUCT; BY PRODUCT INHIBITION; CHEMICAL INTERMEDIATE FOR SYNTHESIS OF INDINAVIR, A POTENT HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITOR | MERCK & CO., INC. | 2001-01-09 | — | — | US | claimed |
| US-5871981-A | COMPOUNDS FOR TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | claimed |
| US-5858737-A | INCUBATING MIXTURE OF INDENE AND PSEUDOMONAS PUTIDA TO GIVE DESIRED ISOMER OF INDANDIOL | MERCK & CO., INC. (US) | 1999-01-12 | — | — | US | claimed |
| CN-1147243-A | Regiospecific process for the preparation of cis-1-amino-2-alkanols from epoxides | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| CN-1147244-A | Regiospecific processes to make cis-1-amino-2-alkanol from diol or halohydrin | MERCK & CO INC (US) | 1997-04-09 | — | — | CN | claimed |
| US-5489710-A | AMINATION BY MIXING WITH NITRILE SOLVENT, ACIDIFICATION AND HYDROLYZING WITH WATER | MERCK & CO., INC. (US) | 1996-02-06 | — | — | US | claimed |
| US-5449830-A | Enzyme inhibitors for protease encoded for HIV | MARCK & CO., INC. (US) | 1995-09-12 | — | — | US | claimed |
| US-5420353-A | Protease inhibitors, AIDS | MERCK & CO., INC. (US) | 1995-05-30 | — | — | US | claimed |
| US-8357524-B2 | Chemically modified mutant serine hydrolases show improved catalytic activity and chiral selectivity | DANISCO US INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120295329-A1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-11-22 | — | — | US | disclosed |
| US-20120156721-A1 | CHEMICALLY MODIFIED MUTANT SERINE HYDROLASES SHOW IMPROVED CATALYTIC ACTIVITY AND CHIRAL SELECTIVITY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | US | disclosed |
| US-8148128-B2 | Chemically modified mutant serine hydrolases show improved catalytic activity and chiral selectivity | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-04-03 | — | — | US | disclosed |
| US-5420353-A | Protease inhibitors, AIDS | MERCK & CO., INC. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
| EP-0552309-A1 | NEW PROCESS FOR BIOPHOSPHORYLATING ORGANIC COMPOUNDS | MERCK & CO. INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992006992-A2 | NEW PROCESS FOR BIOPHOSPHORYLATING ORGANIC COMPOUNDS | MERCK & CO., INC. (US) | 1992-04-30 | — | — | WO | disclosed |